Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027820 · ClinicalTrials.gov registry record · Phase 1
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
A Phase 1 study of Chronic Myelomonocytic Leukemia and Clear Cell Renal Cell Carcinoma, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 10
- Study locations
NCT00027820 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Clear Cell Renal Cell Carcinoma that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 106 participants, above the 87-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (22% higher). The trial reports 10 study locations across 9 states.
The verdict
NCT00027820, a Phase 1 study of Chronic Myelomonocytic Leukemia and Clear Cell Renal Cell Carcinoma, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer. Stem cells are "seed cells" necessary to make blood cells. Researchers want to see if using less radiation and less chemotherapy with new immune suppressing drugs will enable a stem cell transplant to work. Researchers are hoping to see a mixture of recipient and donor stem cells after transplant. This mixture of donor and recipient stem cells is called "mixed-chimerism". Researchers hope to see these donor cells eliminate tumor cells. This is called a "graft-versus-leukemia" response.
Conditions Studied
Interventions
- RADIATION Total-Body Irradiation
- DRUG Fludarabine Phosphate
- PROCEDURE Peripheral Blood Stem Cell Transplantation
- DRUG Cyclosporine
- PROCEDURE Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Study Locations (10)
Other
- Universitaet Leipzig - Leipzig
- University of Torino - Torino
Arizona
- University of Arizona Health Sciences Center - Tucson
California
- Stanford University Hospitals and Clinics - Stanford
Georgia
- Emory University/Winship Cancer Institute - Atlanta
Oregon
- OHSU Knight Cancer Institute - Portland
Texas
- Baylor Medical Center at Garland - Garland
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027820
The ClinicalTrials.gov registry entry for NCT00027820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (22% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Total-Body Irradiation is the first listed.
NCT00027820 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00027820 about?
NCT00027820 is a clinical study titled "Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer". This phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer. Stem cells are "seed cells" necessary to make blood cells. Researchers want to see if using less radiation and less chemotherapy with new im...
What is the current status of trial NCT00027820?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2001-08. Estimated completion is 2004-09-05.
What conditions does trial NCT00027820 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, Adult Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Childhood Acute Lymphoblastic Leukemia in Remission.
What interventions are being tested in trial NCT00027820?
The interventions under investigation include: Total-Body Irradiation (RADIATION), Fludarabine Phosphate (DRUG), Peripheral Blood Stem Cell Transplantation (PROCEDURE), Cyclosporine (DRUG), Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00027820?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027820 being conducted?
This trial has 10 study locations across Arizona, California, Georgia, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Myelomonocytic Leukemia
All registered trials for this condition
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.